Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France

Bogdan Muresanb IQVIA, Health Economics and Outcomes Research, Amsterdam, NetherlandsView further author information

Katie Chanc IQVIA, EMEA HE Real-World Methods & Evidence Generation, London, UKView further author information

Xenia Raduc IQVIA, EMEA HE Real-World Methods & Evidence Generation, London, UKView further author information

Bob G. Schultzd Takeda Pharmaceuticals U.S.A., Inc, US Medical Affairs, Value & Evidence Generation, Lexington, MA, USA

Robin S. Turpine Takeda Pharmaceuticals U.S.A., Inc, US Value Evidence, Bannockburn, IL, USAView further author information

Arnaud Nucitf Takeda France S.A.S, Health Economics - Patient Value & Access, Paris, FranceView further author information

Elisabetta Fenug Takeda Pharmaceuticals International AG, Global Health Economics, Zurich, SwitzerlandCorrespondence[email protected]
View further author information

Your download is now in progress and you may close this window